XLON
EMVC
Market cap16mUSD
Oct 21, Last price
52.50GBP
Name
Netscientific PLC
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
NetScientific plc operates as a venture capital entity, strategically deploying capital into companies at their initial, emergent, and growth stages. Its primary investment interests lie in sustainability, advanced technology, and groundbreaking biomedical and healthcare innovations. Within the healthcare sphere, the firm specifically targets digital health, diagnostics, and therapeutics, with a particular emphasis on ventures that enhance the well-being and health outcomes for individuals suffering from chronic diseases. Its digital health focus encompasses data analytics, wearable technologies, and various medical devices. Geographically, NetScientific actively seeks opportunities in established European markets and across the United States. While typical investments may reach £15 million (approximately $20.32 million), the firm is prepared to commit larger sums. A core strategy is to secure a controlling interest in its principal subsidiary companies, with funding predominantly sourced from its own balance sheet. NetScientific plc was established in 2008 and is headquartered in London, United Kingdom.
Key people
Charles Spicer
Independent Non-Executive Chairman of the Board · since 2023
Aneshkumar Patel
Group Chief Financial Officer · since 2025
Edward Hooper
Executive Director, General Counsel · since 2022
Ilian Iliev
Chief Executive Officer, Executive Director · since 2020
Stephen Crowe
Portfolio CFO, Company Secretary · since 2025
Jonathan Robinson
Senior Independent Non-Executive Director · since 2023
Headquarters & legal address
London End
Beaconsfield, BKM HP9 2JH
GB
Beaconsfield, BKM HP9 2JH
GB
Previous name
NETSCIENTIFIC LIMITED
Previous name
GREYBRIDGE IT LIMITED
Previous name
NETSCIENTIFIC PLC
Valuation
Title GBP in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||